Cannabis as Medicine

The cannabinoids dronabinol (Marinol, and generics) and nabilone (Cesamet) are effectivefor treatment of chemotherapy-induced nausea and vomiting, for which they have been approved in the US. Cannabinoid products may also be effective for second-line treatment of cancer pain and the neuropathic pain and spasticity of multiple sclerosis, but none are currently approved for these indications. […]

Conclusion: “Our data indicate that infrequent users have a stronger relationship with negative mood. Our data suggested that those that use cannabis casually scored higher on the CES-D scale for depression, and consequently could be at greater risk for developing pre-depression symptomology compared to both chronic users and controls.” For more

By Will Boggs MD(Reuters Health) – Pregnant women who use marijuana to treat their nausea may be harming their unborn children, according to a warning from the National Institute on Drug Abuse (NIDA). “Although more research is needed, there is strong reason to believe marijuana could be harmful to fetal development,” NIDA director Dr. Nora

Download Document

Written by Marie Ellis Published: Friday 9 December 2016 Parkinson’s disease is the second most common neurological illness in the United States, causing tremors, slowness of movement, postural instability, and impaired balance and coordination. But findings from a new review suggest symptoms of the condition could be improved with marijuana. A new review suggests medical

At the 70th annual meeting of the American Epilepsy Society in Houston this week, GW Pharmaceuticals announced results of the first ever randomized, double-blind, placebo-controlled studies of CBD. The company’s proprietary CBD drug is called Epidiolex. In the Dravet syndrome study, 43 percent of patients taking Epidiolex had a greater than or equal to 50 percent

Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol José A. S. Crippa1*, Ana C. S. Crippa2, Jaime E. C. Hallak1, Rocio Martín-Santos1,3and Antonio W. Zuardi1 1Department of Neuroscience and Behavior, University of São Paulo, Ribeirão Preto, Brazil 2Department of Clinical Medicine, Federal University of

London, UK; 26 Sept 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: “GWP,” “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® (cannabidiol or

Check out this article For full article

States have passed so-called “medical marijuana” laws under the theory that pot has medicinal benefits that can’t be produced by other, legal means. But what if there was a Food and Drug Administration-approved drug that gave you all the benefits of the active ingredients in marijuana, such as tetrahydrocannabinol (THC) or cannabidiol? What if that